Peripheral Arterial Disease
Recent clinical, regulatory, research and industry developments relating to this disease.
Expanding the Paradigm for Cardiovascular Palliative Care.
Epidemiology of Peripheral Artery Disease and Polyvascular Disease.
Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review.
Global vascular guidelines on the management of chronic limb-threatening ischemia.
Epidemiology of peripheral artery disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 5 clinical trials expected to report results, the earliest in Q4 2027.
- Q4 2027A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of Subcutaneously Administered SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
- Q4 2027An Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel® in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease.
- Q4 2027Vascular Trial Associated Registry Pilot: Antiplatelet Therapies for Patients Undergoing Lower Extremity Endovascular Revascularization
- Q2 2028A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial
- Q4 2029Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk: A Randomized Trial
Clinical MilestonesViewHide
- 2026-07-07A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled TrialResults expected Q2 2028
- 2026-04-29A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of Subcutaneously Administered SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial DiseaseResults expected Q4 2027
- 2026-04-13Vascular Trial Associated Registry Pilot: Antiplatelet Therapies for Patients Undergoing Lower Extremity Endovascular RevascularizationResults expected Q4 2027
- 2026-03-24Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk: A Randomized TrialResults expected Q4 2029
- 2025-09-09An Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel® in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease.Results expected Q4 2027
- 2025-09-01REducing Diabetic MacrovascUlar Complications DuE to Peripheral Arterial Disease- REDUCE-PADPrimary completion
- 2026-07-07ClinicalA Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled TrialResults expected Q2 2028
- 2026-06-05ClinicalEffects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial DiseaseResults posted
- 2026-04-29ClinicalA Phase 2a Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of Subcutaneously Administered SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial DiseaseResults expected Q4 2027
- 2026-04-13ClinicalVascular Trial Associated Registry Pilot: Antiplatelet Therapies for Patients Undergoing Lower Extremity Endovascular RevascularizationResults expected Q4 2027
- 2026-03-24ClinicalLow Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk: A Randomized TrialResults expected Q4 2029
- 2025-09-09ClinicalAn Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel® in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease.Results expected Q4 2027
- 2025-09-01ClinicalREducing Diabetic MacrovascUlar Complications DuE to Peripheral Arterial Disease- REDUCE-PADPrimary completion
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Secondary prevention of atherothrombotic events Clopidogrel is indicated in: Adult patie… (2015)
Approval — Hypercholesterolaemia and mixed dyslipidaemia Repatha is indicated in adults with primary… (2015)
Approval — Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Red… (2010)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Peripheral Arterial Disease2
- Angioplasty, Balloon, Coronary1
- Ankle Brachial Index1
- Global Health1
- Heart Defects, Congenital1
- Heart Failure1
- Lower Extremity1
- Ocimum basilicum1
Leading journals6
- Circulation2
- Circulation research2
- Cardiovascular therapeutics1
- European heart journal1
- Journal of vascular surgery1
- Lancet (London, England)1
Leading researchers8
- Aboyans V3
- Bradbury AW2
- Criqui MH2
- Matsushita K2
- Ricco JB2
- Aday AW1
- Bartelink MEL1
- Bate GR1
Affiliations (unnormalised)6
- University of California2
- Advocate Lutheran General Hospital1
- Baylor College of Medicine1
- Birmingham Clinical Trials Unit1
- Center of Thrombosis and Haemostasis1
- Department of Biomedical and Preclinical Sciences1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Peripheral arterial disease is a disorder of reduced blood flow to the extremities, most often due to atherosclerosis. It is commonly recognized by intermittent claudication and can be identified noninvasively by an ankle-brachial index of 0.9 or less. The literature also emphasizes that asymptomatic disease is more common than symptomatic claudication.
The supplied grounding identifies atherosclerosis as the cause of peripheral arterial disease. The chronic limb-threatening ischemia guidance also notes that PAD-related limb ischemia is distinct from venous, traumatic, embolic, and nonatherosclerotic causes, which are excluded from that syndrome definition.
Peripheral arterial disease reflects impaired perfusion of the lower extremities from atherosclerotic narrowing of the arteries. This reduced blood flow can produce intermittent claudication and, in more severe disease, limb ischemia with rest pain, ulceration, gangrene, and risk of amputation. The literature also links PAD with broader atherosclerotic cardiovascular morbidity and mortality.
Age is a major risk factor, with prevalence and incidence rising sharply in older adults. The supplied abstracts also indicate association with coexisting atherosclerotic disease and cardiovascular morbidity, but they do not provide a fuller risk-factor list.
Management is described at the level of vascular evaluation and intervention rather than specific drug regimens. For chronic limb-threatening ischemia, the guidance emphasizes urgent referral to a vascular specialist, accurate staging of limb threat, and management that may include surgery. The grounding does not support a more detailed medication-based standard of care for PAD.
AI-generated summary grounded in MeSH and 5 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.